A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer

Journal of Molecular Medicine

Volumn 92, Issue 9, 2014, Pages 969-981

  Lin, Chiao Yun ^a,b   Chao, Angel ^a,b   Wang, Tzu Hao ^a,b,c   Hsueh, Swei ^a,b   Lee, Yun Shien ^b,d   Wu, Tzu I ^e   Chao, An Shine ^a   Huang, Huei Jean ^a,b   Chou, Hung Hsueh ^a,b   Chang, Ting Chang ^a,b   Lai, Chyong Huey ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d MING CHUAN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

EGFR; Endometrial cancer; HER2; Lapatinib; MMP1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERSTITIAL COLLAGENASE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SYNAPSIN I; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MMP1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME REPRESSION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; PATIENT SELECTION; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 84906327367     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1163-0     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
2. Honda T, Urabe R, Kurita T, Kagami S, Kawagoe T, Toki N, Matsuura Y, Hachisuga T (2012) Trends in the demographic and clinicopathological characteristics in Japanese patients with endometrial cancer, 1990-2010. Int J Womens Health 4:207-212
3. Cancer Registry Annual Report, 2010 Taiwan: Ministry of Health and Welfare, Executive Yuan 2012. http://www.hpa.gov.tw/BHPNet/English/Index.aspx. Accessed 20 Aug 2013
4. Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL (2012) The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer 130:2629-2637
5. Creasman WT, Miller DS (2012) Adenocarcinoma of the uterine corpus. In: Di Saia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG (eds) Clinical gynecologic oncology, 8th edn. Elsevier, Philadelphia, pp 141-174
6. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67-73
7. Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316:1083-1100
8. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A et al (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 286:18756-18765
9. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW et al (2008) Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 98:1076-1084 (Pubitemid 351399811)
10. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P et al (2012) Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127:345-350
11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
12. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267-5273
13. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128
14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388
15. Bao W, Fu HJ, Jia LT, Zhang Y, Li W, Jin BQ, Yao LB, Chen SY, Yang AG (2010) HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys 499:49-55
16. Armstrong DA, Phelps LN, Vincenti MP (2009) CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells. Mol Cancer Res 7:1517-1524
17. D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL (2007) Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 101:279-284 (Pubitemid 46169881)
18. Park YH, Jung HH, Ahn JS, Im YH (2008) Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun 377:389-394
19. Park S, Jung HH, Park YH, Ahn JS, Im YH (2011) ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochem Biophys Res Commun 407:680-686
20. Knopfova L, Benes P, Pekarcikova L, Hermanova M, Masarik M, Pernicova Z, Soucek K, Smarda J (2012) c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis. Mol Cancer 11:15
21. Wang YP, Liu IJ, Chiang CP, Wu HC (2013) Astrocyte elevated gene-1 is associated with metastasis in head and neck squamous cell carcinoma through p65 phosphorylation and upregulation of MMP1. Mol Cancer 12:109
22. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, Lee YS, Chen JK, Lin YJ, Chang PY, Wang CJ et al (2010) Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics 9:1873-1884
23. Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS et al (2012) Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene 31:764-775
24. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrade F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P et al (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102:134-143
25. Nishida M (2002) The Ishikawa cells from birth to the present. Hum Cell 15:104-117
26. Lin CY, Tan BC, Liu H, Shih CJ, Chien KY, Lin CL, Yung BY (2010) Dephosphorylation of nucleophosmin by PP1beta facilitates pRB binding and consequent E2F1-dependent DNA repair. Mol Biol Cell 21:4409-4417
27. Snoek-van Beurden PA, Von den Hoff JW (2005) Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38:73-83 (Pubitemid 40139420)
28. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167 (Pubitemid 30428195)
29. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, Clark IM (2003) The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem 278:10304-10313 (Pubitemid 36800292)
30. Moser PL, Kieback DG, Hefler L, Tempfer C, Neunteufel W, Gitsch G (1999) Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. Anticancer Res 19:4391-4393 (Pubitemid 30042795)
31. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354 (Pubitemid 40637826)
32. Kumler I, Tuxen MK, Nielsen DL (2014) A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 40:259-270
33. Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62:3151-3158 (Pubitemid 34602408)
34. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R et al (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230
35. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639 (Pubitemid 43259947)
36. Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y et al (2008) HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 14:7861-7870
37. LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD (2009) The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int J Cancer 125:2957-2969